Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention

Retail sentiment was particularly strong for healthcare stocks today, as Monte Rosa, Autonomix, and Evoke Pharma each announced positive developments regarding their respective innovations.
Retail is most bullish on these stocks today | Source: Pexels
Retail is most bullish on these stocks today | Source: Pexels
Profile Image
Prabhjote Gill·Stocktwits
Updated Jul 02, 2025 | 8:31 PM GMT-04
Share this article

Monte Rosa Therapeutics Inc. ($GLUE)

Screenshot 2024-10-28 132438.png
Monte Rosa Therapeutic's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits

Shares of Monte Rosa Therapeutics surged over 130% on Monday, reaching a two-year high of $12.15 after announcing an exclusive global licensing agreement with Novartis AG ($NVS). 

The collaboration focuses on developing innovative treatments for immune-related conditions, particularly MRT-6160, an oral drug designed to inhibit the degradation of VAV1, a key signaling protein for T and B cell receptors. 

As part of the agreement, Novartis will pay $150 million upfront for exclusive worldwide rights to MRT-6160 and other VAV1-targeting molecular glues, with Monte Rosa eligible for up to $2.1 billion in milestones and tiered royalties on international sales.

Retail sentiment on Stocktwits surged to ‘extremely bullish’ (97/100) with ‘extremely high’ (97/100) message volume.

Evoke Pharma Inc. ($EVOK)

Screenshot 2024-10-28 132459.png
Evoke Pharma's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits

Evoke Pharma’s shares were up over 30% on Monday following its presentation of positive data for its lead drug, Gimoti, as a treatment option for diabetes gastroparesis.

The company ranked among the top 10 trending stocks on Stocktwits, secured the second spot for most watched, and was listed in the top 20 most active stocks on Monday afternoon.

Evoke Pharma and its partner, Eversana, found that patients using Gimoti, a nasal version of metoclopramide, experienced significant improvements compared to those using the oral formulation. Patients who received the nasal treatment had reduced healthcare resource use and fewer healthcare visits.

Retail sentiment on Stocktwits surged into ‘extremely bullish’ territory (97/100) with ‘extremely high’ (97/100) message volume.

Autonomix Medical Inc. ($AMIX)

Screenshot 2024-10-28 132518.png
Autonomix Medical's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits

Shares of Autonomix skyrocketed by more than 90% on Monday morning following the announcement of positive results from its clinical trial aimed at alleviating pain in pancreatic cancer patients. 

The stock became the second-highest trending on Stocktwits, just behind Trump Media & Technology Group Corp. ($DJT), and was listed among the top 10 most watched stocks of the day.

Retail sentiment on Stocktwits surged to ‘extremely bullish’ (97/100) with chatter escalating into ‘extremely high’ (97/100) territory.

For updates and corrections email newsroom@stocktwits.com.

Subscribe to The Daily Rip
All Newsletters
Get the daily email that keeps you tuned in and makes markets fun again.

Read more: MicroStrategy’s Bitcoin Holdings Drive Historic High: Retail Unfazed

Read about our editorial guidelines and ethics policy